Frequently Asked Questions
Find Answers to the Questions that Matter Most
From those delivering care to those seeking it.
Clinician Questions
How is ALZpathDx (available from Neurocode) used in Alzheimer’s disease diagnosis?
ALZpathDx may serve as a diagnostic tool for Alzheimer’s disease, particularly in individuals who are experiencing cognitive changes. Elevated levels of pTau217 in the blood may indicate the presence of Alzheimer’s disease pathology. While a definitive diagnosis of Alzheimer’s disease often requires a combination of clinical assessments, cognitive tests, imaging studies, and sometimes cerebrospinal fluid (CSF) analysis, measuring pTau217 levels in the blood could potentially serve as a complementary tool for diagnosing Alzheimer’s disease specific pathology. ALZpathDx may aid in differentiating Alzheimer’s disease from other types of dementia or cognitive disorders. By assessing pTau217 levels alongside other biomarkers and clinical data, healthcare providers may be better equipped to accurately diagnose Alzheimer’s disease pathology.
Can ALZpathDx indicate the stage or severity of AD?
Currently, ALZpathDx is used to identify underlying AD pathology but does not offer a prognosis on disease severity or progression.
How does ALZpathDx compare to CSF and PET scans?
Recent research shows that pTau217 blood tests perform comparably to pTau217 measured in cerebrospinal fluid (CSF) for the diagnosis of Alzheimer’s disease. ALZpathDx also demonstrates exceptional accuracy in detecting amyloid and tau positivity, distinguishing the presence of tau tangles in amyloid-positive individuals, and tracks closely with PET imaging results.
Does kidney disease interfere with the results?
Recent research shows that blood-based biomarkers increase as a function of CKD, but when controlling for age, sex, and amyloid positivity, ALZpath pTau217 was not significantly different, suggesting renal function does not have a clinically relevant impact when using this highly accurate blood-based biomarker.
What codes will I need to use and what reimbursement will I receive?
There is a general, but no specific CPT code for this test. Currently, this test is patient-pay only.
How do I order the test?
To order the ALZpathDx blood collection kit, fill out the requisition form and a batch order will be sent to your office. More information can be found on the Neurocode website.
Is the testing done in our office, or does the patient need to go elsewhere for the blood draw?
Both options are available, depending on your in-office blood collection capabilities.
Do you offer other biomarker testing?
Neurocode and BC Neuroimmunology offer other biomarker testing. For clinical interpretation, we recommend using pTau217 in patients 55 and older who are experiencing cognitive or memory concerns, as it is specific for detecting Alzheimer’s disease pathology in the brain.
How long does it take to receive the results?
Results are typically available within 3-5 business days.
Patient Questions
How is the test administered?
The ALZpathDx test requires a simple blood draw, typically conducted in a physician’s office or certified laboratory.
How do I order the test?
At this time, the test must be ordered by your primary care provider. They will need to complete a requisition form from our partner laboratories, Neurocode or BC Neuroimmunology (Canada only), and the test will be shipped directly to their office.
Can I purchase the test without going through my medical provider?
Your doctor must order the ALZpathDx test for you. We can provide your doctor with information to help them understand the test and how to order it.
Can I order the test for a loved one?
The test must be ordered for each patient individually, but you may support your loved one in receiving a requisition form from their doctor.
How will I receive my results?
Your results will be sent to your provider through a secure portal, and they will discuss the next steps with you.
Should I get tested if I have no symptoms?
pTau217 testing is currently intended for individuals experiencing cognitive symptoms or memory concerns. Ongoing research is exploring its potential use in people at risk but not yet symptomatic, with the goal of enabling earlier detection and intervention in the future.
Should I get tested if I have symptoms of cognitive decline?
If you are experiencing memory issues or other cognitive symptoms, a pTau217 blood test may help clarify whether Alzheimer’s disease could be contributing – providing guidance for the next steps.
How old must I be to receive ALZpathDx?
ALZpathDx is intended for individuals 55 and older who are experiencing cognitive or memory concerns.
What does ALZpathDx show?
Elevated levels of pTau217 in the blood may indicate the presence of Alzheimer’s disease pathology.
What should I do if my blood biomarker levels are abnormal?
Follow up with your healthcare provider for further evaluation and guidance.
Is ALZpathDx offered outside of the US and Canada?
Yes, please contact us to learn more.
Will insurance cover the test?
Currently, the test is not covered by insurance.
How much does the test cost?
$349.
Who do I speak to about billing questions in the US?
Please email customercare@neurocode.com
Who do I speak to about billing questions in Canada?
Please email mary@bcneuro.ca
Is ALZpathDx approved by the FDA?
Currently, the test is not FDA-approved.
Researcher Questions
How do I access the RUO version of the pTau217 test?
The RUO (Research Use Only) version of the test can be accessed by ordering through our partners by filling out the form on Our Science page.
What is the sensitivity/specificity of this test?
The pTau217 test has a PPV/NPV of 95% depending on the cut-off. Amyloid AUC: 0.957, Tau AUC: 0.952.
Alzheimer's Disease Questions
What is Alzheimer’s disease?
Alzheimer’s disease is a progressive neurodegenerative disorder that gradually damages brain cells, leading to worsening memory loss, confusion, and difficulties with thinking, problem-solving, and language. Over time, it affects a person’s ability to conduct daily activities and maintain independence. It is the most common cause of dementia in older adults.
What causes Alzheimer’s disease?
The exact cause of Alzheimer’s disease is not fully understood. However, it is believed to result from a combination of genetic, environmental, and lifestyle factors. Abnormal protein deposits in the brain—such as amyloid plaques and tau tangles—are hallmarks of the disease, and these changes disrupt communication between brain cells and eventually lead to cell death.
How is Alzheimer’s disease diagnosed?
Diagnosis of Alzheimer’s disease involves a comprehensive evaluation. This typically includes a review of the patient’s medical history, interviews with family members, cognitive and memory assessments, and neurological exams. Doctors may also use brain imaging (such as MRI or PET scans) and laboratory tests, including blood tests or spinal fluid analysis, to help rule out other conditions and support the diagnosis.
What is the difference between Alzheimer’s disease and dementia?
Dementia is a general term for a decline in cognitive function severe enough to interfere with daily life. Alzheimer’s disease is the most common cause of dementia, but there are other types as well, such as vascular dementia and Lewy body dementia. In other words, all Alzheimer’s disease is dementia, but not all dementia is Alzheimer’s disease.
Biomarker Questions
What is a biomarker?
A biomarker is a measurable substance or characteristic in the body—such as a protein, gene, or molecule—that provides information about a biological process, disease state, or response to treatment. In Alzheimer’s disease, biomarkers help clinicians identify and monitor the presence and progression of the disease, often before symptoms appear.
What are blood biomarkers?
Blood biomarkers are specific indicators that can be detected through a simple blood test. In Alzheimer’s disease, these biomarkers—such as certain forms of amyloid and tau proteins—can reveal changes in the brain long before cognitive symptoms develop. Blood-based biomarkers are less invasive, more accessible, and more cost-effective than traditional methods like spinal fluid analysis or brain imaging, making early detection and monitoring easier for patients and clinicians
What is pTau217?
pTau217 is a specific form of the tau protein that has been modified by the addition of phosphate groups (phosphorylation). It is closely linked to Alzheimer’s disease pathology and is considered one of the most reliable blood biomarkers for detecting the disease. Elevated levels of pTau217 in the blood strongly correlate with the presence of amyloid plaques and tau tangles in the brain, which are hallmarks of Alzheimer’s disease.
What causes a build-up of pTau217?
A build-up of pTau217 occurs when tau proteins in the brain become abnormally phosphorylated, causing them to form tangles inside nerve cells. These tau tangles disrupt cell function and are a key feature of Alzheimer’s disease. The accumulation of pTau217 reflects underlying disease processes that contribute to memory loss and cognitive decline.
What is the ALZpathDx test?
The ALZpathDx test is available from Neurocode and is a blood-based diagnostic tool designed to measure levels of pTau217. By detecting this specific biomarker, the test helps clinicians identify and monitor Alzheimer’s disease more accurately and at earlier stages than traditional methods. This enables earlier intervention and better tracking of disease progression and response to treatments.
Are there risks associated with blood biomarker testing?
Blood biomarker testing is generally safe and minimally invasive. The main risks are minor and may include temporary discomfort, slight pain, or bruising at the site where blood is drawn. Serious complications are very rare.
More Questions?
Connect With Us
If you want to learn more about ALZpath or our work, we’re here to talk.
